GlassScriptPhysician profile
Sucai Bi
NPI 1659363794
$5,453.05
in general payments reported to CMS, 2019-2025
22 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $309 · 2021: $78.54 · 2022: $4,297 · 2023: $109 · 2024: $50.96 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $4,127.21 | 2022 | |
| Seagen INC. | $213.02 | 2019-2023 | Adcetris |
| Pfizer INC. | $191.69 | 2019-2024 | |
| Celgene Corporation | $98.29 | 2019-2024 | Reblozyl, Pomalyst |
| Amgen INC. | $92.58 | 2019-2022 | |
| Janssen Biotech, INC. | $89.90 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $84.68 | 2023-2025 | |
| Tempus Ai, INC | $82.78 | 2025 | Xt Cdx |
| Sanofi-Aventis U.S. LLC | $74.95 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $71.92 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $62.50 | 2019-2020 | |
| Daiichi Sankyo INC. | $44.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.45 | 2019-2020 | |
| Genzyme Corporation | $36.96 | 2019-2020 | |
| Abbvie INC. | $32.70 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.84 | 2019-2020 | |
| Incyte Corporation | $19.15 | 2020 | |
| Secura Bio, INC. | $17.15 | 2019 | |
| Janssen Scientific Affairs, LLC | $14.02 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Verastem, INC. | $11.22 | 2020 | |
| Lilly USA, LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sucai Bi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.